Desflurane

Visiongain Report Offers Transformative Insights on the $11.8bn Anaesthesia Drugs Market

Retrieved on: 
Wednesday, April 24, 2019
Medical specialties, Chemical compounds, Organic compounds, Local anesthetics, General anesthetics, Anilides, Anesthesia, Nicotinic antagonists, General anaesthesia, Chloroprocaine, Desflurane, Lidocaine

LONDON, April 24, 2019 /PRNewswire/ -- Local Anaesthesia, General Anaesthesia, Inhalation Anaesthesia, Intravenous Anaesthesia, Topical Anaesthesia, Benzocaine, Bupivacaine, Chloroprocaine, Lidocaine, Prilocaine, Ropivacaine, Desflurane, Dexmedetomidine, Midazolam, Propofol, Remifentanil, Sevoflurane and Others

Key Points: 
  • LONDON, April 24, 2019 /PRNewswire/ -- Local Anaesthesia, General Anaesthesia, Inhalation Anaesthesia, Intravenous Anaesthesia, Topical Anaesthesia, Benzocaine, Bupivacaine, Chloroprocaine, Lidocaine, Prilocaine, Ropivacaine, Desflurane, Dexmedetomidine, Midazolam, Propofol, Remifentanil, Sevoflurane and Others
    The global anaesthesia drugs market is expected to reach $11.8bn in 2024 and is estimated to grow at a CAGR of 3.9% from 2019-2024.
  • The local anaesthesia segment accounted for the largest share in the anaesthesia drugs market in 2018.
  • The 241-page report provides clear detailed insight into the global anaesthesia drugs market.
  • To request sample pages from this report please contact Sara Peerun at [email protected] or refer to our website: https://www.visiongain.com/report/global-anaesthesia-drugs-market-2019-2...
    Along with revenue prediction for the overall world market for anaesthesia drugs market, our investigation shows forecasts to 2029 forthe market segmented by type:
    This report also provides revenue forecast to 2029 for theselocal anaesthesia drugs:

Inhalation Anesthesia: Worldwide Market Analysis Report 2018-2025 - The Increasing Concern About Greenhouse Gas Emissions is Hampering Growth

Retrieved on: 
Thursday, November 8, 2018
Chemistry, Neurochemistry, GABAA receptor positive allosteric modulators, General anesthetics, Organic chemistry, Nicotinic antagonists, Organofluorides, Ethers, Desflurane, Sevoflurane, Isoflurane, Anesthesia

The "Inhalation Anesthesia Market Size, Share & Trends Analysis Report By Application (Induction, Maintenance), By Product (Sevoflurane, Desflurane, Isoflurane), And Segment Forecasts, 2018 - 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Inhalation Anesthesia Market Size, Share & Trends Analysis Report By Application (Induction, Maintenance), By Product (Sevoflurane, Desflurane, Isoflurane), And Segment Forecasts, 2018 - 2025" report has been added to ResearchAndMarkets.com's offering.
  • The global inhalation anesthesia market size is expected to reach USD 1.4 billion by 2025, exhibiting 3.5% CAGR during the forecast period.
  • Hence, these drugs are the preferred choice for patients who are critically injured and require a shorter duration of anesthesia.
  • The global inhalation anesthesia market, by product, was dominated by sevoflurane with a revenue share of 70% in 2017.

The global inhalation anesthesia market size is expected to reach USD 1.4 billion by 2025

Retrieved on: 
Tuesday, September 25, 2018
Chemistry, Neurochemistry, GABAA receptor positive allosteric modulators, General anesthetics, Nicotinic antagonists, Organofluorides, Organic chemistry, Ethers, Desflurane, Sevoflurane, Isoflurane, Compound annual growth rate

Inhalation Anesthesia Market Size, Share & Trends Analysis Report By Application (Induction, Maintenance), By Product (Sevoflurane, Desflurane, Isoflurane), And Segment Forecasts, 2018 - 2025

Key Points: 
  • Inhalation Anesthesia Market Size, Share & Trends Analysis Report By Application (Induction, Maintenance), By Product (Sevoflurane, Desflurane, Isoflurane), And Segment Forecasts, 2018 - 2025
    The global inhalation anesthesia market size is expected to reach USD 1.4 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting 3.5% CAGR during the forecast period.
  • Hence, these drugs are the preferred choice for patients who are critically injured and require a shorter duration of anesthesia.
  • The global inhalation anesthesia market, by product, was dominated by sevoflurane with a revenue share of 70.0% in 2017.
  • North America accounted for the dominant revenue share of 40.6% in the global market in 2017, followed by Europe.